Ankylosing spondylitis and Uveitis

From a western clinical perspective, uveitis and ankylosing spondylitis (AS) are linked by genetics and immune pathways. HLA‑B27, present in many with axial spondyloarthritis, is also common in acute anterior uveitis (AAU). Mechanistic work implicates misfolding‑induced ER stress and activation of the IL‑23/IL‑17 axis. Epidemiologically, AAU occurs in roughly one‑quarter to one‑third of AS patients, and a notable proportion of individuals presenting with HLA‑B27 AAU have unrecognized axial disease. This bidirectional relationship guides screening and treatment. Clinically, AAU presents abruptly with unilateral ocular pain, redness, and photophobia, often recurring and alternating between eyes. Complications—posterior synechiae, elevated intraocular pressure, cataract, and cystoid macular edema—underscore the need for urgent ophthalmology assessment. Uveitis can precede inflammatory back pain by years; thus, rheumatology referral is appropriate when AAU coexists with features such as buttock pain, heel enthesitis, psoriasis, or inflammatory bowel disease. Diagnostic anchors include slit‑lamp confirmation of anterior chamber cells/flare, intraocular pressure measurement, and a dilated fundus exam. Laboratory work may include HLA‑B27 and inflammatory markers; MRI of the sacroiliac joints (STIR sequences) helps confirm axial spondyloarthritis. Infectious causes of uveitis must be excluded before corticosteroids are used. Management integrates local and systemic care. Topical corticosteroids and mydriatics are first‑line for AAU. For recurrent or severe disease—or when axial disease is active—systemic therapy is considered. Monoclonal anti‑TNF agents (adalimumab, infliximab) are effective for AS and have strong evidence for reducing uveitis flares; etanercept is less protective for the eye. Sulfasalazine and methotrexate can reduce recurrence in some patients, particularly with peripheral arthritis. IL‑17 inhibitors treat axial disease but have not shown efficacy in noninfectious uveitis trials; JAK inhibitors are effective for AS with limited ocular data. Safety is central: screen for TB and hepatitis prior to biologics; monitor for steroid‑related ocular hypertension and cataract; and counsel on NSAID risks. Coordinated ophthalmology–rheumatology follow‑up supports flare prevention, vision preservation, and shared decision‑making.

Eastern traditions view the eye and spine as expressions of whole‑body balance. In Traditional Chinese Medicine (TCM), a sudden, painful red eye with photophobia suggests exuberant heat or wind‑heat affecting the Liver channel, while axial stiffness and deep sacroiliac aching may reflect ‘Bi syndrome’—obstruction by wind, cold, and damp, or damp‑heat in the lower burner. Therapy aims to clear heat from the eye, dispel dampness, move qi and blood along the Du and Bladder channels, and support constitutional resilience. In Ayurveda, inflammatory eye conditions fall under Abhishyanda; axial inflammatory arthritis is linked to ama (toxic, undigested material) obstructing channels. Approaches emphasize pacifying excess heat/inflammation, improving digestion (agni), and gentle detoxification under supervision. As adjuncts to biomedical care, acupuncture may help relieve axial pain, stiffness, and stress reactivity—factors that can influence flare perception—though direct evidence for preventing uveitis is limited. Herbal strategies (e.g., formulas to clear heat/damp in TCM; botanicals such as turmeric/haridra and guduchi in Ayurveda) are traditionally used to modulate inflammatory tone. Modern research on curcumin suggests anti‑inflammatory activity, but robust trials in uveitis or axial spondyloarthritis are still emerging. Dietary guidance aligns with whole‑food, anti‑inflammatory patterns—emphasizing vegetables, omega‑3–rich foods, and fermented items as tolerated—paralleling interest in the microbiome’s role in HLA‑B27 conditions. Mind–body practices (qigong, yoga, meditation) can improve pain coping and autonomic balance, potentially reducing stress‑related exacerbations. Importantly, all complementary measures should be coordinated with ophthalmology and rheumatology to avoid interactions (e.g., herbs with immunomodulators) and to ensure prompt steroid and biologic therapy when indicated to protect vision.